This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.
Laleh Amiri-Kordestani, MD
Advertisement
Articles by Laleh Amiri-Kordestani, MD
Advertisement
Latest Updated Articles
- Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives
Published: November 16th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
5
